Auditoriet er åpent for publikum, men disputasen vil også bli strømmet. Opptaket av disputasen vil være tilgjengelig i et døgn. The auditorium is open to the public. The defense will still be streamed. A recording of the disputation will be available for 24 hours.
Populærvitenskapelig sammendrag av avhandlingen/ Summary of the thesis
How does testicular cancer (TC) treatment influence the subsequent risk for a second TC, a second cancer other than TC and mortality?
Complete TC treatment details were retrieved for all men diagnosed with TC in Norway 1980-2009 (n=5724) and linked with the Cancer Registry of Norway and the Norwegian Cause of Death Registry.
Treatment with cisplatin-based chemotherapy reduced the second TC risk compared with surgery, with a further risk reduction for each additional cycle administered. Older age at first TC also reduced the risk. Compared with the general population, treatment with chemotherapy and/or radiotherapy was associated with an increased risk of a second cancer and of premature mortality. Additionally, increased second cancer risk was observed after treatment with surgery only. Young age at TC diagnosis was associated with the highest risk of second cancer or mortality compared with the general population.
This information is important for health personnel and TC survivors.
Veiledere/ Supervisors: Hovedveileder/Main supervisor: Professor Hege Sagstuen Haugnes, Institutt for klinisk medisin, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet. Biveiledere/supervisors: Professor Roy-Martin Bremnes, Institutt for klinisk medisin, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet. Professor emerita Sofie Fosså, Oslo University Hospital.
Bedømmelseskomité/Defensecomitee: Professor Flora Van Leeuwen, Netherlands Canser Institute – 1. opponent. Professor Christian Beisland, Universitetet i Bergen – 2. opponent. Førsteamanuensis Tone Nordøy, Institutt for klinisk medisin, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet – leder av komité.
Disputasleder/ Leader of defense: Professor Øyvind Nilssen, Institutt for klinisk medisin, Det helsevitenskapelige fakultet, UiT Norges arktiske universitet.